Canada Markets closed

Addex Therapeutics Ltd (ADDXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.56000.0000 (0.00%)
At close: 08:55AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.5600
Open1.5600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.5600 - 1.5600
52 Week Range1.5600 - 1.6500
Volume5,000
Avg. Volume0
Market Cap50.58M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.4430
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.00
  • GlobeNewswire

    Addex to Present at the Swiss Equities Baader Virtual Conference

    Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Swiss Equities Baader Virtual Conference taking place January 12 - 14th, 2022. Yesterday, Baader Helvea Equities issued an initiation coverage report on Addex with a buy rating, describing the company as “an underdog stock with potential to hit

  • GlobeNewswire

    Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

    Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference. In his presentation, which is scheduled for Monday, January 10, 2021 at 07:00 EST / 13:00 CET, Mr Dyer will provide a corporate update and discuss recent developments at Addex. A video of the present

  • GlobeNewswire

    Addex Raises $10.0 Million in Equity Financing

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Capital LLC, a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares (“A